The Parkinson fatigue scale

Brown, Richard G.; Dittner, Antonia; Findley, L J; Wessely, Simon

doi:10.1016/j.parkreldis.2004.07.007

Cited by 280 publications

(226 citation statements)

References 17 publications

Supporting

Mentioning

215

Contrasting

Unclassified

Order By: Relevance

“…The correlation analysis revealed that fatigue was an independent predictor of poor HRQoL in female patients. Fatigue is a subjective feeling, which referred to a state of extreme tiredness, weakness, lack of energy, or exhaustion physically, mentally, or both [22]. Physical fatigue in PD patients may be caused by physical limitation such as rigidity or slow speed of repetitive movements due to parkinsonism.…”

Section: Discussionmentioning

confidence: 99%

Gender Differences of Nonmotor Symptoms Affecting Quality of Life in Parkinson Disease

et al. 2017

View full text Add to dashboard Cite

Background/Aims: Gender differences of health-related quality of life (HRQoL) in patients with various disorders have been reported. Various nonmotor symptoms (NMSs) also affect the patients' lives and HRQoL, even in the early stages of Parkinson disease (PD). Our study aimed to identify whether there are gender differences of HRQoL in PD patients in the early stages, and which NMSs are associated with HRQoL depending on gender. Method: Eighty-nine PD patients (47 males, 42 females) and 36 healthy controls were enrolled. We evaluated HRQoL, NMSs, and their associations in each gender. Result: The total Parkinson Disease Quality of Life Questionnaire and Beck Anxiety Inventory scores were higher in female patients than in male patients. The correlation analysis revealed no association between NMSs and HRQoL in male patients. In female patients, HRQoL was highly correlated with depression, and moderately associated with fatigue. Conclusions: Gender differences of an association between HRQoL and NMSs exist in PD. We found that fatigue and depression were the main determinants of poor HRQoL in female patients even in the early stages. We suggest that a gender-specific therapeutic approach is important, and it is necessary to pay special attention to the predictors associated with causing poor HRQoL.

show abstract

Section: Discussionmentioning

confidence: 99%

Gender Differences of Nonmotor Symptoms Affecting Quality of Life in Parkinson Disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It was only after the trial was almost complete that a PD specific fatigue scale was validated and published [12]. The fatigue scales we used (FSI and FSS) have previously been used and validated in PD, but are not PD specific [3,4,9].…”

Section: Discussionmentioning

confidence: 99%

Modafinil for Parkinson’s disease fatigue

et al. 2009

View full text Add to dashboard Cite

Fatigue is common in Parkinson's disease (PD), occurring in up to 42% of patients (2). There is no recognized treatment. This is a study of modafinil for Parkinson's disease related fatigue. Ethical approval was given. Patients with idiopathic PD were recruited from a Movement Disorders clinic. Those with depression, dementia, and other causes for fatigue were excluded. Patients were assessed using the Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), self-rating of improvement, Epworth Sleepiness Scale (ESS), and UPDRS. Modafinil was titrated up over 4 weeks to maximum of 400 mg/day. There followed a 5 week maintenance phase before reassessment. Thirteen patients participated. No significant change was seen in any safety measure. The FSS did not change significantly, however those on modafinil rated an improvement in their fatigue compared to placebo. The Modafinil group had a statistically significant improvement on ESS (p < 0.05). This is a small study of modafinil in selected PD patients. There is a suggestion of improvement on the global clinical impression scale for fatigue, but no significant change on FSS. A larger study is needed to further evaluate this drug in PD fatigue. This study highlights the problems with recruitment when trialing treatments of non-motor symptoms in PD. A significant improvement in EDS was seen.

show abstract

“…Cognitive function was assessed by the Korean version of the Mini-Mental State Examination (K-MMSE), the Korean version of the Montreal Cognitive Assessment (MoCA-K), and the Frontal Assessment Battery (FAB) [15-17]. The severity of non-motor symptoms was assessed by the Non-Motor Symptoms Scale (NMSS), the Parkinson’s Disease Questionnaire (PDQ-39), the Parkinson’s Disease Sleep Scale (PDSS), the Beck Depression Inventory (BDI), the Beck Anxiety Inventory (BAI), the Neuropsychiatric Inventory (NPI), and the Parkinson Fatigue Scale (PFS) [15-24]. …”

Section: Methodsmentioning

confidence: 99%

Association between White Matter Lesions and Non-Motor Symptoms in Parkinson Disease

et al. 2018

View full text Add to dashboard Cite

Background: There are only few studies exploring the relationship between white matter lesions (WMLs) and non-motor symptoms in Parkinson disease (PD). This study aimed to investigate the association between WMLs and the severity of non-motor symptoms in PD. Methods: The severity of motor dysfunction, cognitive impairment, and non-motor symptoms was assessed by various scales in 105 PD patients. We used a visual semiquantitative rating scale and divided the subjects into four groups: no, mild, moderate, and severe WMLs. We compared the means of all scores between the four groups and analyzed the association between the severity of WMLs and the specific domain of non-motor symptoms. Results: The non-motor symptoms as assessed by the Non-Motor Symptoms Scale, Parkinson’s Disease Questionnaire (PDQ-39), Parkinson’s Disease Sleep Scale, Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Neuropsychiatric Inventory (NPI), and Parkinson Fatigue Scale (PFS) were significantly worse in the patients with moderate and severe WMLs than in those without WMLs. Compared with the no WML group, the scores for motor dysfunction were significantly higher in the mild, moderate, and severe WML groups. The scores for cognitive dysfunction were significantly higher in the patients with severe WMLs than in those without WMLs. The severity of WMLs showed linear associations with PFS, BDI, BAI, NPI, and PDQ-39 scores. The severity of WMLs also correlated linearly with scores for motor and cognitive dysfunction. Conclusions: Among the non-motor symptoms, fatigue, depression, anxiety, and quality of life were significantly affected by WMLs in PD. Confirmation of the possible role of WMLs in non-motor symptoms associated with PD in a prospective manner may be crucial not only for understanding non-motor symptoms but also for the development of treatment strategies.

show abstract

The Parkinson fatigue scale

Cited by 280 publications

References 17 publications

Gender Differences of Nonmotor Symptoms Affecting Quality of Life in Parkinson Disease

Gender Differences of Nonmotor Symptoms Affecting Quality of Life in Parkinson Disease

Modafinil for Parkinson’s disease fatigue

Association between White Matter Lesions and Non-Motor Symptoms in Parkinson Disease

Contact Info

Product

Resources

About